• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

PCA3: Predictive performance superior to PSA, fPSA

Article

Researchers are further exploring the diagnostic and prognostic utility of PCA3, and data showed that combining PCA3 with free PSA and other risk factors significantly improves the accuracy for predicting biopsy outcomes.

Other studies presented at the meeting examined PCA3's ability to discrminate between significant and insignificant cancer and the methodology for urine specimen collection.

In a prospective, multicenter study, James B. Amberson, MD, and colleagues investigated the performance of PCA3, free PSA, and PSA as single variables and in combination for predicting the outcome of biopsy (12 to 14 cores) in 463 men referred because of an elevated PSA or abnormal DRE. All but three men (99%) had valid PCA3 assay results, and the cohort had a positive biopsy rate of 44%.

"These analyses suggest there is significant potential to combine PCA3 and free PSA with other risk factors to develop a nomogram that will better predict biopsy outcome," said Dr. Amberson, a uropathologist in Stratford, CT, who serves as medical director of Dianon Systems, Inc., Shelton, CT.

Related Videos
Akhil Das, MD, FACS, answers a question during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.